Bli medlem
Bli medlem

Du är här

2020-07-03

Invent Medic Sweden: Invent Medic's product Efemia bladder support included in Swedish online pharmacy Apotea's assortment

With this agreement in place, Efemia will soon be available to buy from three major pharmacy companies in Sweden, as similar agreement have already been signed with Apoteket AB and Apotek Hjärtat.

"We are excited about this agreement with Apotea regarding the inclusion of Efemia in their assortment. This agreement will make Efemia even more visible and available for Swedish women with stress urinary incontinence (SUI)," says Invent Medic's CEO Karin Bryder.

Karin Bryder is satisfied with the company's success when it comes to signing agreements and initiating collaborations for Efemia in Sweden since the market launch in the fall of 2018. Today, the product is available both through the public healthcare system and private entities.

"With Apotea included, we now have agreements with three major pharmacy companies and seven healthcare regions in Sweden. We also have a very successful collaboration with the non-profit women's health organisation 1.6 & 2.6 million club. Our joint campaigns and lectures have contributed to that many Swedish women with SUI have discovered Efemia and are now able to life a more active and healthy life."

Efemia's availability in Sweden
Apoteket AB (in 33 pharmacies and on apoteket.se (https://www.apoteket.se))
Apotek Hjärtat (apotekhjartat.se (https://www.apotekhjartat.se))
Apotea (www.apotea.se from the summer of 2020)
Region Jämtland Härjedalen
Region Norrbotten (via Onemed)
Region Blekinge (from October 2020)
Region Kronoberg (from October 2020)
Region Värmland
Västra Götalandsregionen

Efemia's availability in international markets
Belgium
Denmark
Germany
The Netherlands (approved for subscription with cost coverage)
Norway (approved for prescription with cost coverage)
The UK (approved for prescription with cost coverage in England)
 

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.